Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

Novo Nordisk, the Danish company behind Ozempic and Wegovy, made one very dumb decision a few years ago that's now poised to massively eat into its profits — a wild twist in the pharma company's ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

I take a GLP-1 medication, and it’s made a real difference in my life. But not everyone who needs these medications can get them. If you’re on Medicaid, the situation is even worse. Too often ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Gastrointestinal issues are common in patients taking GLP-1 weight loss drugs like Ozempic and Wegovy, but there are some lesser known side effects that range from bothersome to bizarre.

Women taking weight-loss jabs are being warned they must use effective contraception, after the injections were linked to a “baby boom”. The UK's Medicines and Healthcare products Regulatory ...

Ozempic and Wegovy have been hailed as wonder drugs when it comes to weight loss. But as the drug has become more widely used, a number of unintended side-effects have become apparent—with the ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy, might also double as a brain booster. Research out today describes a link between semaglutide use and a reduced ...

Ozempic and Wegovy generated combined sales of DKK 50.1 billion in the first quarter of 2025, accounting for around 66% of the company’s total revenues.